This article was originally published in Start Up
Achaogen Inc. is developing drugs around a genetic mechanism that, instead of killing bacteria, weakens their ability to defend themselves. By so doing, it intends to cut off bacterial resistance at its source, so that existing antibiotics would remain powerful.
You may also be interested in...
For some start-ups, keeping pace with Big Pharma's shifting business priorities means following a path of less resistance. New companies are being formed around Big Pharma assets that no longer fit their priorities and market needs; others are fueled by novel discovery approaches based on elucidating and harnessing the power of natural genetic mechanisms.